Abilify Falters Overseas: Piqued Hunger in Targacept Partnering?
By Randy Osborne
Tuesday, December 1, 2009
Investors must wait until probably next year to find out exactly what the withdrawal of Abilify's European marketing application means for Targacept Inc.'s chances overseas with lead asset TC-5214 in adjunctive depression therapy. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.